OSIP » Topics » Collaborative Development Programs with Pfizer
This excerpt taken from the OSIP 10-K filed Mar 1, 2007.
Programs with Pfizer
From 1986 to 2001, our oncology drug discovery efforts in
targeted therapies were conducted in collaboration with Pfizer.
During the course of the alliance, several novel molecular
targeted therapies, including Tarceva, were advanced to clinical
development. Pfizer is continuing to develop two clinical stage
targeted therapies from this prior alliance: CP-547,632, a VEGFR
inhibitor in Phase II trials, and CP-868,596, a PDGFR
inhibitor in Phase I trials. Pursuant to our agreement with
Pfizer for this collaboration, if Pfizer is successful in
commercializing either of these drug candidates, we will receive
a royalty from Pfizer on the sales of these drugs. If Pfizer
chooses to discontinue development of any of these drug
candidates, we will have the right to pursue development of
them. In 2006, Pfizer ceased development of CP-724,714, a small
molecule HER-2 inhibitor, and rights to this compound were
returned to us. We have chosen not to proceed with development
of this compound at this time.
How risky is your portfolio?
Remember that 401k from 2 jobs ago?
Taking on too much risk? Too little risk? Have no idea?
Skip the spreadsheet. Track your investments automatically.
We tally your portfolio fees so you don't have to.
You're probably paying higher fees than you think.
Translate your investment accounts from Martian to English.